Dr. David Crawford: Triluron now available for knee pain
Dr. David Crawford, an orthopedic surgeon, shares that Fidia
Pharma USA has announced the launch of Triluron, a hyaluronic acid-based
intra-articular viscosupplement that is indicated for the treatment of pain in
osteoarthritis of the knee for patients who have failed to respond adequately
to the usual medications for the condition. The product contains 20mg of sodium
hyaluronate, administered via intra-articular injection weekly for a total of
three injections. As of press time, it has not yet been established if a single
cycle of less than three injections is as effective as the regular cycle. The
product is supplied in 2 ml vials or 2 ml pre-filled syringes and is intended
for single use. Bilateral treatment requires the use of separate vials or
syringes for each knee.
The chemical formulation of Triluron is identical to the
company’s five-injection regimen, Hyalgan. Studies conducted by the company
show that Triluron was not inferior compared to Hyalgan based on a
retrospective analysis of data collected from two randomnized controlled
trials. Health care providers must be aware of patients’ allergies and exercise
caution when injecting the product into patients who are allergic to avian
proteins, feathers, and egg products, as Triluron is extracted from rooster
combs.
Hyaluronic acid works by acting as a lubricant and shock
absorber, so the joints are able to move fluidly. It also interferes with
prostaglandins and cytokines, naturally occurring compounds that promote
inflammation. It may also coax the joint into increasing its own production of
this substance, which ultimately helps in preserving the cartilage, thus
possibly slowing the disease down. Dr. David Crawford recommends patients to
discuss this option with their surgeons, especially if they are no longer able
to tolerate the pain with ibuprofen or other nonsteroidal anti-inflammatory
drugs, which can cause side effects such as stomach bleeding and kidney problems.
Comments
Post a Comment